Dr.Hoenle AG

HNL

Equity

ISIN DE0005157101 / Valor 1174437

Xetra (2024-09-16)

EUR 11.90-1.24%

Dr.Hoenle AG
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Dr. Hoenle AG is a global leader in the development, manufacturing, and distribution of UV technology, with a diversified portfolio that spans across various industries and applications. The company's business encompasses a wide range of UV solutions including but not limited to, adhesives, coatings, printing inks, and disinfection equipment. Through its subsidiaries, such as Eleco Panacol, EFD, SAS Eltosch Grafix, and others, Dr. Hoenle AG offers specialized products and services tailored to meet the specific needs of its clients. These subsidiaries operate in different regions around the world, including Europe, Asia, and North America, ensuring a global reach and support network for its customers. The company's expertise in UV technology positions it as a key player in sectors that require precision and high-quality UV curing solutions, from industrial manufacturing processes to healthcare applications. Dr. Hoenle AG's commitment to innovation and quality, combined with its extensive product range and international presence, makes it a prominent and respected name in the UV technology industry.

Summarized from source with an LLMView SourceSector: Technology

Revenue Decline

Dr.Hoenle AG reported a revenue of €72.1 million for the third quarter of 2024, which is a 9.6% decrease compared to the same period last year. This decline is attributed to a weak market environment and delays in order intake.

Operating Result Improvement

The operating result (EBIT) for Dr.Hoenle AG in Q3 2024 was -€0.1 million, showing a significant improvement from the -€6.8 million reported in the same quarter of the previous year. This improvement is despite the ongoing challenges in the market.

Positive Cash Flow

Dr.Hoenle AG achieved a positive operating cash flow of €4.6 million in the third quarter of 2024. This positive cash flow is a notable achievement given the overall challenging market conditions.

Outlook for Second Half

The management of Dr.Hoenle AG remains optimistic about a revival in business activities in the second half of the fiscal year 2024. They anticipate an increase in both revenue and earnings during this period.

First Quarter Performance

In the first quarter of the fiscal year 2023/24, Dr.Hoenle AG experienced lower revenues and earnings compared to the same period last year. This was primarily due to a weak market environment in the machinery and plant engineering sectors, as well as delays in order fulfillment.

Summarized from source with an LLMView Source

Key figures

-41.7%1Y

-74.6%3Y

-75.5%5Y

Performance

37.6%1Y

44.0%3Y

44.6%5Y

Volatility